Meeting
2022 ASCO Genitourinary Cancers Symposium
Cost effectiveness of adjuvant pembrolizumab after nephrectomy for RCC: Insights for patient selection from a Markov model.
Authors
Vidit Sharma
Mayo Clinic Department of Urology, Rochester, MN
Vidit Sharma , Kevin M Wymer , Daniel D. Joyce , James P. Moriarty , Bijan J Borah , R. Houston Thompson , Brian Addis Costello , Bradley C. Leibovich , Stephen A. Boorjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 321)
DOI
10.1200/JCO.2022.40.6_suppl.321
Abstract #
321
Poster Bd #
L3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cost-effectiveness of gemcitabine plus cisplatin with and without durvalumab in patients with advanced cholangiocarcinoma.
First Author: J. Alberto Maldonado
Poster
2022 ASCO Annual Meeting
Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.
First Author: Christie Zettler
Poster
2021 ASCO Annual Meeting
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
First Author: Christopher Lemmon
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness-analysis of different treatment modalities in bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NIMBC).
First Author: Constantin Rieger